Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial (Q35555905)

8 August 2017

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial (English)

1 reference

8 August 2017

1 reference

C Antoni

1

1 reference

8 August 2017

G G Krueger

2

1 reference

8 August 2017

K de Vlam

3

1 reference

8 August 2017

C Birbara

4

1 reference

8 August 2017

A Beutler

5

1 reference

8 August 2017

C Guzzo

6

1 reference

8 August 2017

B Zhou

7

1 reference

8 August 2017

L T Dooley

8

1 reference

8 August 2017

A Kavanaugh

9

1 reference

8 August 2017

IMPACT 2 Trial Investigators

10

1 reference

8 August 2017

language of work or name

English

0 references

publication date

27 January 2005

1 reference

Annals of the Rheumatic Diseases

8 August 2017

1 reference

8 August 2017

64

1 reference

8 August 2017

8

1 reference

8 August 2017

1150-1157

1 reference

Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients

8 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Psoriasis causes as much disability as other major medical diseases

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

12 July 2018

Arthritis in psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Deoxyribonucleic acid antibody: a method to detect its primary interaction with deoxyribonucleic acid.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Methotrexate and histologic hepatic abnormalities: a meta-analysis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Severe Psoriasis – Oral Therapy with a New Retinoid

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

An immunofluorescent method usingcrithidia luciliae to detect antibodies to double-stranded DNA

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755609

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

26 September 2018

1 reference

12 December 2020

Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid

1 reference

12 December 2020

Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991

1 reference

12 December 2020

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

12 December 2020

Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of disability and quality of life in rheumatoid and psoriatic arthritis

1 reference

12 December 2020

Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation

1 reference

12 December 2020

Efficacy of infliximab in resistant psoriatic arthritis

1 reference

12 December 2020

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2004.032268

1 reference

8 August 2017

1 reference

8 August 2017

1 reference